Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Towards consensus in acquisition and image analysis of PET and SPECT in the assessment of cardiac sympathetic innervation: a mini-review: a mini-review
Published in: Clinical and Translational Imaging
Access to document
10.1007/s40336-018-00309-w
document
In the rapidly evolving field of nuclear medicine, imaging cardiac sympathetic innervation using both conventional nuclear medicine and PET tracers is a small but growing field of interest. Recent larger clinical trials have underlined the importance of imaging cardiac sympathetic innervation as well as the consequences of low regional tracer accumulation for patient outcomes. New developments have resulted in the introduction of novel PET tracers with high clinical potential, especially for imaging centers without an on-site cyclotron. Despite the generated guidelines, especially on MIBG scintigraphy, widespread compliance with...
Non-invasive estrogen receptor assessment by [F-18]-fluorestradiol(FES)-PET or circulating tumor cells predicts receptor status in patients with metastatic breast cancer
Published in: Cancer Research
Access to document
10.1158/1538-7445.SABCS18-PD4-09
B. Eisses, L. Angus, B. van der Vegt, A. M. Sieuwerts, J. Kraan, J. W. Martens, A. W. Glaudemans, A. H. Brouwers, O. S. Hoekstra, W. Oyen, J. Emmering, S. Gerritse, C. W. Menke-van der Houven van Oordt, E. Boon, C. M. van Herpen, A. Jager, S. Sleijfer, E. G. de Vries, C. P. Schröder
General Assembly, Diagnosis, Imaging: Proceedings of International Consensus on Orthopedic Infections
Published in: Journal of Arthroplasty
Access to document
10.1016/j.arth.2018.09.073
document
Claudio Diaz-Ledezma, René Espinosa-Mendoza, Jiří Gallo, Andor Glaudemans, Felipe Gómez-García, Stuart Goodman, Milan Kaminek, Theo L.B. Le Roux, Adolfo Llinás, Eva Nieslanikova, Libuse Quinn, Peter Sculco, Michal Svoboda
FDG-PET/CT for Detecting an Infection Focus in Patients With Bloodstream Infection: Factors Affecting Diagnostic Yield
Published in: Clinical Nuclear Medicine
Access to document
10.1097/RLU.0000000000002381
document
PURPOSE: To investigate the diagnostic performance of F-fluoro-2-deoxy-D-glucose (FDG) PET/ CT for the detection of an infection focus in patients with a bloodstream infection (BSI) and to identify factors influencing the diagnostic yield of FDG-PET/CT. METHODS: This retrospective single-center study included 185 consecutive patients with a BSI who underwent an FDG-PET/CT scan for the detection of an infection focus between 2010 and 2017. The final diagnosis at hospital discharge was used as reference standard. Diagnostic performance of FDG-PET/CT for the detection of an infection focus was assessed, and...
Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-018-4192-z
document
INTRODUCTION: Invasive fungal infections (IFIs) occur mostly in immunosuppressed patients and can be life-threatening. Inadequate treatment is associated with high morbidity and mortality. We examined the role of 2-fluorodeoxyglucose positron emission tomography integrated with CT (FDG-PET/CT) in monitoring IFIs and therapy decision-making, and evaluated the role of baseline metabolic parameters in predicting the metabolic response. METHODS: All patients between October 2009 and March 2018, diagnosed with IFIs, treated with antifungal drugs, and who underwent FDG-PET/CT at baseline and at one or more timepoints during treatment were retrospectively included....
Alfred O Ankrah, Lambert F R Span, Hans C Klein, Pim A de Jong, Rudi A J O Dierckx, Thomas C Kwee, Mike M Sathekge, Andor W J M Glaudemans